Immutep (IMM) Shares Skyrocket 101% Following FDA Orphan Drug Status for Cancer Treatment

Key Highlights

• Shares of Immutep skyrocketed more than 101% following the FDA’s Orphan Drug Designation award for eftilagimod alfa (efti).
• The designation applies to soft tissue sarcoma treatment, a rare malignancy impacting under 200,000 Americans.
• The status provides seven-year market exclusivity rights, tax incentives, waived fees, and enhanced regulatory assistance.
• Supporting evidence comes from Phase II EFTISARC-NEO clinical trial results, achieving primary objectives in 38 participant evaluations.
• Recent termination of the TACTI-004 Phase III study is projected to push the company’s financial runway past Q2 2027.

Shares of Immutep experienced remarkable growth on Wednesday, more than doubling in value after the Australian biotechnology firm secured Orphan Drug Designation (ODD) from the United States Food and Drug Administration for eftilagimod alfa, its primary oncology candidate.

Immutep Limited, IMMP

The company, trading on the Australian Securities Exchange, recorded a substantial 101.3% surge to reach A$0.079 throughout Wednesday’s trading session.

The designation from the FDA encompasses efti’s application in treating soft tissue sarcoma (STS), representing a rare form of cancer with significant unmet therapeutic requirements across the United States.

Receiving ODD status delivers numerous strategic advantages: specialized regulatory consultation, possible tax incentive programs, exemption from various application fees, and exclusive marketing rights spanning seven years upon final approval.

Supporting evidence for the FDA’s determination originated from the Phase II EFTISARC-NEO clinical investigation. This research evaluated efti combined with radiation therapy and Merck’s KEYTRUDA (pembrolizumab) among patients diagnosed with operable soft tissue sarcoma prior to surgical intervention.

Among 38 assessed participants, the investigation successfully achieved its principal objective. Researchers documented a median tumour hyalinization/fibrosis percentage of 51.5%, significantly surpassing the predetermined threshold of 35% and the conventional baseline of approximately 15% typically observed with radiation therapy exclusively.

Findings remained consistent throughout various sarcoma classifications. Researchers characterized the safety assessment as promising, noting zero postponements to scheduled surgical procedures.

TACTI-004 Program Termination

This encouraging FDA development arrives weeks following Immutep’s decision to discontinue its TACTI-004 Phase III investigation in early March. That particular study evaluated efti for initial treatment of non-small cell lung cancer.

An Independent Data Monitoring Committee advised termination of the study based on futility determinations. The organization is currently executing an organized closure of TACTI-004.

Immutep indicated that discontinuing this trial will significantly extend its available capital resources well beyond the originally forecasted Q2 2027 timeframe.

Development Portfolio and Financial Position

Apart from STS and pulmonary cancer initiatives, Immutep maintains five LAG-3 focused programs. Among these, IMP761 is presently undergoing Phase I evaluation for autoimmune condition applications.

The organization reported a net deficit of A$61.4 million during the 2025 fiscal period, representing an increase from A$42.7 million recorded in 2024.

As a pre-revenue biotechnology enterprise, Immutep continues requiring additional capital infusions to maintain ongoing research and development operations.

The company preserves collaborative arrangements with leading pharmaceutical corporations, including Merck (MSD), facilitating advancement of its therapeutic pipeline.

The EFTISARC-NEO study results, which formed the foundation for Wednesday’s FDA designation approval, incorporated translational observations aligned with efti’s operational mechanism — immune system stimulation through LAG-3 engagement.